###### Strengths and limitations of this study

-   The strengths of our findings lie in the large sample size, the 10-year follow-up period, and the standardised methodology.

-   Our findings are limited by the lack of data, precluding adjustment for pneumococcal and influenza vaccinations, which have been associated with reduced mortality among patients hospitalised with pneumonia.

-   We have not identified factors (specimen quality or antimicrobial treatments) that may influence community-acquired pneumonia outcomes because these variables were not collected in the Spanish Hospital Discharge Database.

-   We did not classify diabetic patients into groups based on the therapy used to control blood glucose, with the result that we were unable to provide data on the control of blood glucose during the hospitalisation.

Introduction {#s1}
============

Prevalence of diabetes is steadily rising. In Spain, the number of people with diabetes has more than doubled over the last decade due to an increasing obesity rate and an ageing population.[@R1] This increase in diabetes prevalence is projected to lead a significant increase in patients with community-acquired pneumonia (CAP).[@R2]

CAP is a leading infectious cause of hospitalisation worldwide, particularly among people with diabetes.[@R3] Previous studies have shown that diabetes is a risk factor for a pneumonia-related hospitalisation.[@R6] A population-based cohort study found that the adjusted relative risk (RR) for pneumonia-related hospitalisation among subjects with diabetes was 1.26 (95% CI 1.21 to 1.31) compared with non-diabetic patients.[@R4]

Advanced age and comorbidity are associated with increased mortality among adults hospitalised with CAP.[@R9] Diabetic patients may have increased susceptibility to pneumonia for several reasons. They are at increased risk of hyperglycaemia, decreased immunity, impaired lung function and chronic complications such as heart disease, renal failure and pulmonary microangiopathy.[@R10] Kornum *et al*[@R5] concluded that presence of type 2 diabetes mellitus (T2DM) predicts increased pneumonia-related mortality. However, Kaplan *et al*[@R11] reported no association between in-hospital mortality (IHM) and diabetes.

The incidence of pneumonia may be increasing.[@R3] [@R9] [@R12] Secular trends in incidence and outcomes of CAP among patients with and without T2DM have been examined.[@R4] However, to the best of our knowledge, no previous studies have investigated national trends in the incidence, characteristics and outcomes of CAP in people with diabetes in Spain.

In this study, we used national hospital discharge data to examine trends in incidence and outcomes of CAP among patients with or without T2DM in Spain from 2004 to 2013. In particular, we analysed patient comorbidities, diagnostic and therapeutic procedures, pneumonia pathogens and in-hospital outcomes, such as readmission, IHM and length of hospital stay (LOHS).

Methods {#s2}
=======

We performed a retrospective, observational study using the Spanish National Hospital Discharge Database (Conjunto Mínimo Básico de Datos (CMBD)), which compiles all public and private hospital data, covering more than 98% of hospital admissions.[@R13] The CMBD includes patient variables (sex, date of birth), admission and discharge dates, up to 14 discharge diagnoses, and up to 20 procedures performed during the hospital stay.[@R13] We analysed data collected between 1 January 2004 and 31 December 2013 for subjects aged 40 and over.

The criteria for diseases and procedures were defined according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), which is used in the Spanish CMBD.

We selected admissions for patients with a primary diagnosis of CAP (ICD-9-CM codes: 480--488, 507.0--507.8). We grouped admissions by diabetes status as follows: T2DM (ICD-9-CM codes: 250.x0 and 250.x2) or no diabetes in any diagnostic position. We excluded people with type 1 diabetes mellitus (ICD-9-CM codes: 250.x1; 250.x3).

Clinical characteristics included information on overall comorbidity at the time of diagnosis, which was assessed by calculating the Charlson Comorbidity Index (CCI).[@R14] We divided patients into three categories: low index, which corresponds to patients with no previously recorded disease; medium index, patients with one disease category; and high index, patients with two or more disease categories.

Irrespective of the position at the diagnoses coding list, we retrieved data about comorbidities as described by Kornum *et al* (2007).[@R5] Also, we specifically identified the following procedures: computerised axial tomography (CAT) of thorax (ICD-9-CM code 87.41), bronchial fibroscopy (ICD-9-CM code 33.21--33.24), non-invasive mechanical ventilation (ICD-9-CM code 93.90), invasive mechanical ventilation (ICD-9-CM code 96.7, 96.70, 96.71, 96.72), thoracocentesis (ICD-9-CM code 34.91) and red cell transfusion (ICD-9-CM code 99.03, 99.04).

We analysed pneumonia pathogens documented during hospitalisations for pneumonia using the following ICD-9-CM codes: 481 for *Streptococcus pneumoniae*; 482.84 for *Legionella;* 482.41 and 482.42 for *Staphylococcus aureus;* 482.2 for *Haemophilus influenzae;* and 482.1 for *Pseudomonas aeruginosa*. These were the five most frequently identified pathogens. All others represented under 0.30% of admissions.

We estimated the proportion of readmission (patients that had been discharged from the hospital within the previous 30 days), the median of LOHS and IHM. IHM is defined by the proportion of patients who died during admission for each year of study.

Statistical analysis {#s2a}
--------------------

In order to assess time trends, the age and sex incidence rates of admissions for CAP in patients with T2DM and non-diabetic patients were calculated per 100 000 inhabitants,. We calculated yearly T2DM-specific incidence rates by dividing the number of admissions per year, sex, and age group by the corresponding number of people in that population group using the age-adjusted, sex-adjusted estimated prevalence of T2DM obtained from National Health Surveys (NHS) conducted in 2003/2004, 2006/2007, 2009/2010 and 2011/2012, and based on data from the Di\@bet.es Study, which estimated the prevalence of diabetes in the Spanish population.[@R1] [@R15] From 2001 to 2010, Spanish NHS was published every 2 or 3 years. So diabetic population for missing years (2005 and 2008) was estimated assuming that growth rate was the same thorough the period 2004--2010. We estimated rates by fitting a linear regression model with population from years when NHS was available and we used this model to impute population for 2005 and 2008. We also calculated the yearly, age and sex adjusted-specific incidence rates for non-diabetic patients by dividing the number of cases per year, sex, and age group by the corresponding number of people in that population group (excluding those with T2DM), according to the data from the Spanish National Institute of Statistics, as reported on 31 December of each year.[@R16]

To assess the effect of T2DM on the incidence, we fitted two separate multivariate Poisson regression models for patients with and without T2DM adjusted by sex, age and year of discharge as independent variables. The results of these models are shown as adjusted incidence rate ratio (IRR) with their 95% CIs. A model adjusting by the same independent variables and including diabetes status was also conducted to assess the adjusted effect of diabetes in the incidence of the total population.

To assess whether there was any overinflation, we tried also with models of negative binomial regression, obtaining very similar results so we decided to use conventional Poisson regression models.

A descriptive statistical analysis was performed for all continuous variables and categories by stratifying admissions for CAP according to diabetes status. Variables are expressed as proportions, as means with SDs or as medians with IQRs (LOHS). A bivariate analysis of variables according to year was performed using the χ^2^ test for linear trend (proportions), analysis of variance (ANOVA) (means) and Kruskal-Wallis (medians), as appropriate.

To assess differences between those patients with and without T2DM, for each year and for the total sample, the statistical tests conducted for continuous variables were the Student\'s t-test for normal distributions and the Mann-Whitney test for non-normal distributions; categorical variables were compared using the χ^2^ test and adjusted incidences were compared using Poisson regression. These same tests were used to compare the characteristics of those diabetic patients who died with those who survived to the hospital admission and equally for non-diabetic subjects. Finally, we performed logistic regression analyses with mortality as a binary outcome using the independent variables and age, sex, CCI, readmission, diagnostic and therapeutic procedures, pathogens and year of admission for those with and without diabetes and for the entire population to assess the influence of diabetes on IHM. Estimates were ORs with their 95% CIs. Statistical analyses were performed using Stata V.10.1 (Stata, College Station, Texas, USA). Statistical significance was set at p\<0.05 (two-tailed).

Ethical aspects {#s2b}
---------------

Data confidentiality was maintained at all times in accordance with Spanish legislation. Given the anonymous and mandatory nature of the data set, it was not deemed necessary to obtain informed consent.

Results {#s3}
=======

From 2004 to 2013, we identified a total of 901 136 admissions for CAP as primary diagnosis in patients aged ≥40 years in Spain. Patients with T2DM accounted for 24.8% of total (134 534 men and 89 181 women).

[Table 1](#BMJOPEN2016013097TB1){ref-type="table"} and [table 2](#BMJOPEN2016013097TB2){ref-type="table"} show the incidence and the clinical characteristics, comorbidities, diagnostic and therapeutic procedures and in-hospital outcomes of admissions for CAP in patients with T2DM and in patients without T2DM from 2004 to 2013, respectively.

###### 

Incidence and characteristics of hospital admissions for pneumonia as primary diagnosis in patients with type 2 diabetes in Spain, 2004--2013

                                          2004            2005            2006            2007             2008             2009             2010             2011             2012             2013             Total
  --------------------------------------- --------------- --------------- --------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- -----------------
  N                                       16 161          19 764          17 267          20 913           22 002           24 426           23 377           25 807           27 655           26 343           223 715
  Incidence\* (per 100 000 inhabitants)   812.64          948.39          792.36          959.67           974.43           1045.33          1000.43          962.56           1031.49          923.26           948.84
  Women, n (%)\*                          6476 (40.07)    8060 (40.78)    6632 (38.41)    8364 (39.99)     8678 (39.44)     9880 (40.45)     9240 (39.53)     10 338 (40.06)   11 126 (40.23)   10 387 (39.43)   89 181 (39.86)
  Age, mean (SD)                          75.97 (10.24)   76.06 (10.39)   76.18 (10.47)   76.29 (10.39)    76.91 (10.47)    76.37 (10.98)    77.53 (10.28)    77.64 (10.45)    78.41 (10.15)    78.23 (10.34)    77.08 (10.46)
  40--64 years, n (%)†                    2150 (13.3)     2638 (13.35)    2348 (13.6)     2864 (13.69)     2894 (13.15)     3589 (14.69)     2690 (11.51)     3085 (11.95)     2892 (10.46)     2846 (10.8)      27 996 (12.51)
  65--74 years, n (%)†                    4329 (26.79)    5096 (25.78)    4302 (24.91)    5017 (23.99)     4780 (21.73)     5262 (21.54)     4880 (20.88)     5178 (20.06)     5030 (18.19)     5027 (19.08)     48 901 (21.86)
  75--84 years, n (%)\*                   6385 (39.51)    7925 (40.1)     6962 (40.32)    8468 (40.49)     8972 (40.78)     9782 (40.05)     9749 (41.7)      10 407 (40.33)   11 515 (41.64)   10 651 (40.43)   90 816 (40.59)
  ≥85 years, n (%)\*                      3297 (20.4)     4105 (20.77)    3655 (21.17)    4564 (21.82)     5356 (24.34)     5793 (23.72)     6058 (25.91)     7137 (27.66)     8218 (29.72)     7819 (29.68)     56 002 (25.03)
  AMI, n (%)†                             865 (5.35)      1106 (5.6)      991 (5.74)      1180 (5.64)      1167 (5.3)       1141 (4.67)      958 (4.1)        1098 (4.25)      1184 (4.28)      1057 (4.01)      10 747 (4.8)
  CHF, n (%)\*                            2587 (16.01)    3258 (16.48)    2941 (17.03)    3542 (16.94)     3940 (17.91)     4183 (17.13)     4379 (18.73)     5210 (20.19)     5795 (20.95)     5645 (21.43)     41 480 (18.54)
  PVD, n (%)\*                            950 (5.88)      1205 (6.1)      1041 (6.03)     1249 (5.97)      1239 (5.63)      1391 (5.69)      1371 (5.86)      1681 (6.51)      1728 (6.25)      1874 (7.11)      13 729 (6.14)
  CEVD/HP/PAPL, n (%)\*                   1509 (9.34)     1850 (9.36)     1688 (9.78)     1959 (9.37)      2290 (10.41)     2496 (10.22)     2535 (10.84)     2753 (10.67)     3101 (11.21)     2854 (10.83)     23 035 (10.3)
  Chronic pulmonary disease, n (%)†       5618 (34.76)    6693 (33.86)    5730 (33.18)    6927 (33.12)     7244 (32.92)     7986 (32.69)     7762 (33.2)      8511 (32.98)     9006 (32.57)     8822 (33.49)     74 299 (33.21)
  Dementia, n (%)\*                       1676 (10.37)    1973 (9.98)     1881 (10.89)    2062 (9.86)      2404 (10.93)     2672 (10.94)     2762 (11.82)     3182 (12.33)     3403 (12.31)     3062 (11.62)     25 077 (11.21)
  Renal disease, n (%)\*                  1893 (11.71)    2260 (11.43)    2187 (12.67)    2659 (12.71)     3082 (14.01)     3640 (14.9)      3878 (16.59)     4504 (17.45)     5160 (18.66)     5261 (19.97)     34 524 (15.43)
  Any type of malignancy, n (%)\*         1154 (7.14)     1335 (6.75)     1323 (7.66)     1594 (7.62)      1634 (7.43)      1906 (7.8)       1953 (8.35)      2181 (8.45)      2350 (8.5)       2338 (8.88)      17 768 (7.94)
  Any liver disease, n (%)                793 (4.91)      1001 (5.06)     879 (5.09)      1059 (5.06)      1058 (4.81)      1248 (5.11)      1156 (4.95)      1220 (4.73)      1359 (4.91)      1407 (5.34)      11 180 (5)
  Obesity, n (%)\*                        1240 (7.67)     1593 (8.06)     1400 (8.11)     1766 (8.44)      1754 (7.97)      2339 (9.58)      2167 (9.27)      2599 (10.07)     2671 (9.66)      2822 (10.71)     20 351 (9.1)
  Pleuritis, n (%)†                       913 (5.65)      1263 (6.39)     1107 (6.41)     1299 (6.21)      1391 (6.32)      1393 (5.7)       1326 (5.67)      1511 (5.86)      1611 (5.83)      1481 (5.62)      13 295 (5.94)
  CCI 0, n (%)†                           4646 (28.75)    5726 (28.97)    4905 (28.41)    6175 (29.53)     6162 (28.01)     6782 (27.77)     6064 (25.94)     6429 (24.91)     6835 (24.72)     6237 (23.68)     59 961 (26.8)
  CCI 1, n (%)\*                          8140 (50.37)    9870 (49.94)    8663 (50.17)    10 253 (49.03)   10 951 (49.77)   12 304 (50.37)   11 865 (50.76)   13 141 (50.92)   13 929 (50.37)   13 368 (50.75)   112 484 (50.28)
  CCI≥2, n (%)\*                          3375 (20.88)    4168 (21.09)    3699 (21.42)    4485 (21.45)     4889 (22.22)     5340 (21.86)     5448 (23.3)      6237 (24.17)     6891 (24.92)     6738 (25.58)     51 270 (22.92)
  CAT, n (%)\*                            1441 (8.92)     1759 (8.9)      1701 (9.85)     2229 (10.66)     2447 (11.12)     2656 (10.87)     2725 (11.66)     2929 (11.35)     3100 (11.21)     3071 (11.66)     24 058 (10.75)
  Bronchial fibroscopy, n (%)†            424 (2.62)      516 (2.61)      418 (2.42)      521 (2.49)       540 (2.45)       583 (2.39)       537 (2.3)        564 (2.19)       581 (2.1)        642 (2.44)       5326 (2.38)
  Non-invasive MV, n (%)\*                135 (0.84)      170 (0.86)      160 (0.93)      255 (1.22)       308 (1.4)        387 (1.58)       558 (2.39)       791 (3.07)       946 (3.42)       918 (3.48)       4628 (2.07)
  Invasive MV, n (%)†                     354 (2.19)      462 (2.34)      316 (1.83)      343 (1.64)       346 (1.57)       411 (1.68)       319 (1.36)       388 (1.5)        331 (1.2)        340 (1.29)       3610 (1.61)
  Thoracocentesis, n (%)\*                268 (1.66)      401 (2.03)      311 (1.8)       345 (1.65)       446 (2.03)       439 (1.8)        383 (1.64)       474 (1.84)       452 (1.63)       449 (1.7)        3968 (1.77)
  Red cell transfusion, n (%)\*           512 (3.17)      584 (2.95)      572 (3.31)      718 (3.43)       771 (3.5)        899 (3.68)       899 (3.85)       1054 (4.08)      1219 (4.41)      1051 (3.99)      8279 (3.7)
  Readmission, n (%)\*                    2031 (12.57)    2619 (13.25)    2267 (13.13)    2728 (13.04)     2948 (13.4)      3375 (13.82)     3274 (14.01)     3692 (14.31)     3971 (14.36)     3860 (14.65)     30 765 (13.75)
  LOHS, median (IQR)                      8 (5--13)       8 (5--13)       8 (5--13)       8 (5--12)        8 (5--12)        8 (5--12)        8 (5--12)        7 (5--11)        7 (5--11)        7 (4--11)        8 (5--12)
  IHM, n (%)†                             2232 (13.81)    2728 (13.8)     2345 (13.58)    2619 (12.52)     2797 (12.71)     3167 (12.97)     2987 (12.78)     3415 (13.23)     3728 (13.48)     3256 (12.36)     29 274 (13.09)
  *Streptococcus pneumoniae*, n (%)†      2504 (15.49)    3411 (17.26)    2977 (17.24)    3873 (18.52)     3783 (17.19)     3992 (16.34)     3501 (14.98)     2380 (9.22)      2027 (7.33)      2095 (7.95)      30 543 (13.65)
  *Legionella*, n (%)†                    154 (0.95)      197 (1)         207 (1.2)       189 (0.9)        217 (0.99)       213 (0.87)       197 (0.84)       158 (0.61)       170 (0.61)       159 (0.6)        1861 (0.83)
  *Staphylococcus aureus*, n (%)\*        69 (0.43)       91 (0.46)       104 (0.6)       104 (0.5)        127 (0.58)       157 (0.64)       131 (0.56)       133 (0.52)       171 (0.62)       187 (0.71)       1274 (0.57)
  *Haemophilus influenzae*, n (%)         58 (0.36)       63 (0.32)       57 (0.33)       85 (0.41)        77 (0.35)        76 (0.31)        94 (0.4)         81 (0.31)        92 (0.33)        109 (0.41)       792 (0.35)
  *Pseudomonas aeruginosa*, n (%)         139 (0.86)      159 (0.8)       146 (0.85)      160 (0.77)       160 (0.73)       154 (0.63)       169 (0.72)       184 (0.71)       206 (0.74)       193 (0.73)       1670 (0.75)

Incidence was adjusted by age and sex.

\*p\<0.05 to assess increased time trend from 2004 to 2013.

†p\<0.05 to assess decreased time trend from 2004 to 2013.

AMI, acute myocardial infarction; CAT, computerised axial tomography of thorax; CCI, Charlson Comorbidity Index; CEVD/HP/PAPL, cerebrovascular disease/hemiplegia/paraplegia; CHF, congestive heart failure; IHM, in-hospital mortality; LOHS, length of hospital stay; MV, mechanical ventilation; PVD, peripheral vascular disease.

###### 

Characteristics of hospital admissions for pneumonia as primary diagnosis in patients without type 2 diabetes in Spain, 2004--2013

                                          2004             2005             2006             2007             2008             2009             2010             2011             2012             2013             Total
  --------------------------------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- -----------------
  N                                       56 991           66 996           58 233           66 504           67 123           74 338           67 643           72 762           74 816           72 015           677 421
  Incidence\* (per 100 000 inhabitants)   316.24           355.18           295.55           337.53           333.66           362.07           329.46           348.43           358.27           341.98           338.21
  Women, n (%)\*                          20 375 (35.75)   24 955 (37.25)   21 500 (36.92)   25 263 (37.99)   26 195 (39.03)   29 742 (40.01)   26 715 (39.49)   29 407 (40.42)   30 912 (41.32)   29 455 (40.9)    264 519 (39.05)
  Age, mean (SD)                          73.96 (13.25)    74.26 (13.36)    74.24 (13.64)    74.33 (13.78)    74.79 (13.78)    73.77 (14.61)    75.67 (13.72)    75.65 (13.86)    77.02 (13.28)    76.36 (13.73)    75.06 (13.76)
  40--64 years, n (%)†                    12 471 (21.88)   14 327 (21.38)   13 036 (22.39)   15 012 (22.57)   14 768 (22)      18 992 (25.55)   13 930 (20.59)   15 392 (21.15)   13 497 (18.04)   14 306 (19.87)   145 731 (21.51)
  65--74 years, n (%)†                    12 578 (22.07)   14 150 (21.12)   11 555 (19.84)   12 535 (18.85)   12 153 (18.11)   12 409 (16.69)   11 068 (16.36)   11 581 (15.92)   11 321 (15.13)   10 965 (15.23)   120 315 (17.76)
  75--84 years, n (%)†                    19 395 (34.03)   23 171 (34.59)   19 755 (33.92)   22 482 (33.81)   22 213 (33.09)   23 189 (31.19)   22 555 (33.34)   23 706 (32.58)   24 640 (32.93)   23 151 (32.15)   224 257 (33.1)
  ≥85 years, n (%)\*                      12 547 (22.02)   15 348 (22.91)   13 887 (23.85)   16 475 (24.77)   17 989 (26.8)    19 748 (26.57)   20 090 (29.7)    22 083 (30.35)   25 358 (33.89)   23 593 (32.76)   187 118 (27.62)
  AMI, n (%)\*                            1932 (3.39)      2309 (3.45)      1917 (3.29)      2279 (3.43)      2123 (3.16)      2207 (2.97)      1884 (2.79)      1955 (2.69)      1952 (2.61)      1802 (2.5)       20 360 (3.01)
  CHF, n (%)\*                            6649 (11.67)     7929 (11.84)     6761 (11.61)     8228 (12.37)     8673 (12.92)     9310 (12.52)     9516 (14.07)     10 896 (14.97)   12 004 (16.04)   11 680 (16.22)   91 646 (13.53)
  PVD, n (%)\*                            1857 (3.26)      2345 (3.5)       2121 (3.64)      2239 (3.37)      2237 (3.33)      2445 (3.29)      2496 (3.69)      2753 (3.78)      2923 (3.91)      3074 (4.27)      24 490 (3.62)
  CEVD/HP/PAPL, n (%)\*                   3993 (7.01)      4543 (6.78)      4020 (6.9)       4505 (6.77)      4969 (7.4)       5487 (7.38)      5561 (8.22)      6088 (8.37)      6508 (8.7)       6322 (8.78)      51 996 (7.68)
  Chronic pulmonary disease, n (%)†       20 012 (35.11)   23 065 (34.43)   19 416 (33.34)   21 961 (33.02)   21 810 (32.49)   24 120 (32.45)   22 753 (33.64)   24 112 (33.14)   24 376 (32.58)   23 789 (33.03)   225 414 (33.28)
  Dementia, n (%)\*                       5402 (9.48)      6295 (9.4)       5833 (10.02)     6224 (9.36)      6904 (10.29)     7599 (10.22)     7793 (11.52)     8536 (11.73)     9300 (12.43)     8742 (12.14)     72 628 (10.72)
  Renal disease, n (%)\*                  4363 (7.66)      5327 (7.95)      4609 (7.91)      5760 (8.66)      6328 (9.43)      7189 (9.67)      7312 (10.81)     8278 (11.38)     9609 (12.84)     9572 (13.29)     68 347 (10.09)
  Any type of malignancy, n (%)\*         5696 (9.99)      6420 (9.58)      6006 (10.31)     6671 (10.03)     6929 (10.32)     7642 (10.28)     7504 (11.09)     8234 (11.32)     8289 (11.08)     8407 (11.67)     71 798 (10.6)
  Any liver disease, n (%)                2825 (4.96)      3362 (5.02)      2942 (5.05)      3436 (5.17)      3409 (5.08)      3852 (5.18)      3457 (5.11)      3689 (5.07)      3733 (4.99)      3754 (5.21)      34 459 (5.09)
  Obesity, n (%)\*                        1940 (3.4)       2352 (3.51)      2044 (3.51)      2304 (3.46)      2489 (3.71)      3188 (4.29)      2839 (4.2)       3367 (4.63)      3393 (4.54)      3529 (4.9)       27 445 (4.05)
  Pleuritis, n (%)\*                      3992 (7)         4898 (7.31)      4240 (7.28)      4936 (7.42)      4760 (7.09)      4892 (6.58)      4782 (7.07)      4954 (6.81)      5054 (6.76)      5101 (7.08)      47 609 (7.03)
  CCI 0, n (%)†                           18 620 (32.67)   22 311 (33.3)    19 452 (33.4)    22 643 (34.05)   21 991 (32.76)   24 786 (33.34)   20 436 (30.21)   21 691 (29.81)   21 653 (28.94)   20 550 (28.54)   214 133 (31.61)
  CCI 1, n (%)\*                          28 219 (49.51)   32 726 (48.85)   28 327 (48.64)   31 765 (47.76)   32 752 (48.79)   35 890 (48.28)   33 399 (49.38)   36 155 (49.69)   37 205 (49.73)   35 850 (49.78)   332 288 (49.05)
  CCI≥2, n (%)\*                          10 152 (17.81)   11 959 (17.85)   10 454 (17.95)   12 096 (18.19)   12 380 (18.44)   13 662 (18.38)   13 808 (20.41)   14 916 (20.5)    15 958 (21.33)   15 615 (21.68)   131 000 (19.34)
  CAT, n (%)\*                            5936 (10.42)     6931 (10.35)     6565 (11.27)     8042 (12.09)     8487 (12.64)     9356 (12.59)     9191 (13.59)     9690 (13.32)     9627 (12.87)     10 028 (13.92)   83 853 (12.38)
  Bronchial fibroscopy, n (%)†            2165 (3.8)       2256 (3.37)      2068 (3.55)      2245 (3.38)      2220 (3.31)      2258 (3.04)      2135 (3.16)      2207 (3.03)      2195 (2.93)      2351 (3.26)      22 100 (3.26)
  Non-invasive MV, n (%)\*                442 (0.78)       584 (0.87)       531 (0.91)       718 (1.08)       945 (1.41)       1188 (1.6)       1616 (2.39)      1934 (2.66)      2307 (3.08)      2286 (3.17)      12 551 (1.85)
  Invasive MV, n (%)†                     1426 (2.5)       1700 (2.54)      1140 (1.96)      1338 (2.01)      1405 (2.09)      1520 (2.04)      1279 (1.89)      1516 (2.08)      1336 (1.79)      1287 (1.79)      13 947 (2.06)
  Thoracocentesis, n (%)\*                1271 (2.23)      1476 (2.2)       1308 (2.25)      1527 (2.3)       1549 (2.31)      1655 (2.23)      1502 (2.22)      1508 (2.07)      1518 (2.03)      1636 (2.27)      14 950 (2.21)
  Red cell transfusion, n (%)\*           1830 (3.21)      2125 (3.17)      2034 (3.49)      2189 (3.29)      2498 (3.72)      2642 (3.55)      2709 (4)         2830 (3.89)      3073 (4.11)      3009 (4.18)      24 939 (3.68)
  Readmission, n (%)\*                    6633 (11.64)     7830 (11.69)     7063 (12.13)     7889 (11.86)     8121 (12.1)      8947 (12.04)     8794 (13)        9515 (13.08)     10 427 (13.94)   9716 (13.49)     84 935 (12.54)
  LOHS, median (IQR)                      8 (5--13)        8 (5--13)        8 (5--12)        8 (5--12)        8 (5--12)        7 (4--12)        7 (5--12)        7 (4--11)        7 (4--11)        7 (4--11)        7 (5--12)
  IHM, n (%)†                             8036 (14.1)      9900 (14.78)     8121 (13.95)     8758 (13.17)     9105 (13.56)     9727 (13.08)     9087 (13.43)     10 209 (14.03)   10 777 (14.4)    9803 (13.61)     93 523 (13.81)
  *Streptococcus pneumoniae*, n (%)†      9736 (17.08)     11 685 (17.44)   10 295 (17.68)   12 295 (18.49)   11 899 (17.73)   12 099 (16.28)   10 081 (14.9)    7147 (9.82)      5918 (7.91)      6101 (8.47)      97 256 (14.36)
  *Legionella*, n (%)†                    667 (1.17)       808 (1.21)       727 (1.25)       667 (1)          678 (1.01)       729 (0.98)       668 (0.99)       544 (0.75)       546 (0.73)       449 (0.62)       6483 (0.96)
  *Staphylococcus aureus*, n (%)\*        253 (0.44)       350 (0.52)       286 (0.49)       366 (0.55)       368 (0.55)       378 (0.51)       400 (0.59)       438 (0.6)        503 (0.67)       470 (0.65)       3812 (0.56)
  *Haemophilus influenzae*, n (%)         267 (0.47)       272 (0.41)       257 (0.44)       264 (0.4)        263 (0.39)       293 (0.39)       295 (0.44)       289 (0.4)        300 (0.4)        333 (0.46)       2833 (0.42)
  *Pseudomonas aeruginosa*, n (%)         509 (0.89)       597 (0.89)       514 (0.88)       574 (0.86)       617 (0.92)       622 (0.84)       632 (0.93)       632 (0.87)       638 (0.85)       685 (0.95)       6020 (0.89)

Incidence was adjusted by age and sex.

\*p\<0.05 to assess increased time trend from 2004 to 2013.

†p\<0.05 to assess decreased time trend from 2004 to 2013.

AMI, acute myocardial infarction; CAT, computerised axial tomography of thorax; CCI, Charlson Comorbidity Index; CEVD/HP/PAPL, cerebrovascular disease/hemiplegia/paraplegia; CHF, congestive heart failure; IHM, in-hospital mortality; LOHS, length of hospital stay; MV, mechanical ventilation; PVD, peripheral vascular disease.

Among patients with T2DM, adjusted incidence of admissions for CAP increased significantly from 812.64 cases per 100 000 T2DM population in 2004 to 923.26 cases in 2013 ([table 1](#BMJOPEN2016013097TB1){ref-type="table"}). In patients without T2DM the adjusted incidence of admissions increased significantly from 316.24 cases per 100 000 population without diabetes in 2004 to 341.98 in 2013 ([table 2](#BMJOPEN2016013097TB2){ref-type="table"}). Incidence was significantly higher in people with T2DM than in non-diabetic people for all years analysed. From 2004 to 2013, the adjusted IRR of having CAP admission diagnosis in patients with T2DM was significant and higher than in those without diabetes (IRR 1.27, 95% CI 1.23 to 1.31 vs IRR 1.05, 95% CI 1.03 to 1.07).

Using the Poisson regression model, including the total population and diabetes status as an independent variable, we obtained an adjusted IRR per year of 1.66 (95% CI 1.65 to 1.67) for patients with T2DM using those without diabetes as the reference category. In other words, the incidence of admissions for CAP over the entire period was 1.66-times higher among patients with T2DM than those without diabetes.

In patients who have an admission for CAP, there was a significant male predominance (60.14% for T2DM and 60.95% for no diabetes). Overall, patients with T2DM were significantly older (77.08; SD=10.46 years) than patients without diabetes (75.06; SD=13.76 years) and had more coexisting medical conditions. Specifically, had higher prevalence of acute myocardial infarction (4.8% vs 3.1%), congestive heart failure (18.54% vs 13.53%), cerebrovascular disease/hemiplegia/paraplegia (10.3% vs 7.68%), dementia (11.21% vs 10.72%), renal disease (15.43% vs 10.09%), peripheral vascular disease (6.14% vs 3.62%) and prevalence of obesity is two times higher (all p\<0.05). On the other hand, any type of malignancy and pleuritis were more prevalent in non-diabetic patients (10.6% and 7.03%, respectively) than in those with T2DM (7.94% and 5.94%, respectively). Age and all these comorbidities increased significantly over time in people with T2DM and without diabetes ([table 1](#BMJOPEN2016013097TB1){ref-type="table"} and [table 2](#BMJOPEN2016013097TB2){ref-type="table"}).

As can been seen in [table 1](#BMJOPEN2016013097TB1){ref-type="table"} and [table 2](#BMJOPEN2016013097TB2){ref-type="table"}, acute myocardial infarction and chronic pulmonary disease decreased significantly in both groups over the study period. Male sex percentage increased significantly in people with T2DM and female percentage showed a much larger change over time in patients without T2DM.

We detected a significant increase in use of thorax CAT in both groups over the study period as can been seen in [table 1](#BMJOPEN2016013097TB1){ref-type="table"} and [table 2](#BMJOPEN2016013097TB2){ref-type="table"}.

The use of all therapeutics procedures (except invasive mechanical ventilation which showed a significant decrease) have significantly increased in the last 10 years in diabetic and non-diabetic patients ([table 1](#BMJOPEN2016013097TB1){ref-type="table"} and [table 2](#BMJOPEN2016013097TB2){ref-type="table"}). The use of non-invasive mechanical ventilation has shown an over threefold increase in both groups of patients over the study period.

Of the pathogens analysed the most commonly found was *S pneumoniae*, followed by *Legionella*, *P aeruginosa*, *S aureus* and *H influenzae*.

In year 2013, *S pneumoniae* was detected in 7.95% of diabetic patients and 8.47% in those without the disease. All other pathogens were found in \<1% of patients.

*S pneumoniae* and *Legionella* decreased over time in people with T2DM and without diabetes. However, we detected a significant increase of *S aureus* in both groups over the study period ([table 1](#BMJOPEN2016013097TB1){ref-type="table"} and [table 2](#BMJOPEN2016013097TB2){ref-type="table"}). The prevalence of pathogens analysed was similar in patients with and without the disease.

Readmissions increased in both groups during the study ([table 1](#BMJOPEN2016013097TB1){ref-type="table"} and [table 2](#BMJOPEN2016013097TB2){ref-type="table"}). Among diabetic patients, the increase was from 12.57% in 2004 to 14.65% in 2013. Equivalent figures for subjects without diabetes were significantly lower (11.64% and 13.49%).

Overall median LOHS was significantly higher in patients with T2DM (8 vs7 days). Over time, LOHS following CAP fell significantly in patients with T2DM and without diabetes.

IHM was 13.81% for patients with T2DM and 13.09% for non-diabetic people (p\<0.05). Crude IHM decreased significantly over time in people with T2DM and without diabetes (from 13.81% and 14.1%, respectively, in 2004 to 12.36% and 13.61% in 2013), as can been seen in [table 1](#BMJOPEN2016013097TB1){ref-type="table"} and [table 2](#BMJOPEN2016013097TB2){ref-type="table"}.

[Table 3](#BMJOPEN2016013097TB3){ref-type="table"} shows the characteristics of hospital admissions for CAP in patients with and without T2DM according to IHM during the study period.

###### 

Characteristics of hospital admissions for pneumonia as primary diagnosis in patients with and without type 2 diabetes in Spain, 2001--2013, according to in-hospital mortality

                                         Diabetes         No diabetes                        
  -------------------------------------- ---------------- ---------------- ----------------- ----------------
  Women, n (%)\*†                        76 301 (3924)    12 880 (44)      225 626 (3864)    38 893 (4159)
  Age, mean (SD) \*†                     76.42 (10.51)    81.48 (8.94)     74.11 (13.87)     80.97 (11.43)
  40--64 years, n (%)\*†                 26 507 (13.63)   1489 (5.09)      136 594 (23.39)   9137 (9.77)
  65--74 years, n (%)\*†                 45 070 (23.18)   3831 (13.09)     109 241 (18.71)   11 074 (11.84)
  75--84 years, n (%)\*†                 78 684 (40.47)   12 132 (41.44)   192 709 (33)      31 548 (33.73)
  ≥85 years, n (%)\*†                    44 180 (22.72)   11 822 (40.38)   145 354 (24.89)   41 764 (44.66)
  AMI, n (%)\*†                          9163 (4.71)      1584 (5.41)      17 000 (2.91)     3360 (3.59)
  CHF, n (%)\*†                          35 096 (18.05)   6384 (21.81)     74 122 (12.69)    17 524 (18.74)
  PVD, n (%)\*†                          11 802 (6.07)    1927 (6.58)      20 931 (3.58)     3559 (3.81)
  CEVD/HP/PAPL, n (%)\*†                 18 199 (9.36)    4836 (16.52)     40 554 (6.95)     11 442 (12.23)
  Chronic pulmonary disease, n (%)\*†    67 498 (34.71)   6801 (23.23)     203 108 (34.78)   22 306 (23.85)
  Dementia, n (%)\*†                     18 657 (9.6)     6420 (21.93)     53 446 (9.15)     19 182 (20.51)
  Renal disease, n (%)\*†                29 173 (15)      5351 (18.28)     55 766 (9.55)     12 581 (13.45)
  Any type of malignancy, n (%)\*†       14 089 (7.25)    3679 (12.57)     56 195 (9.62)     15 603 (16.68)
  Any liver disease, n (%)               9730 (5)         1450 (4.95)      29 671 (5.08)     4788 (5.12)
  Obesity, n (%)\*†                      19 076 (9.81)    1275 (4.36)      25 570 (4.38)     1875 (2)
  Pleuritis, n (%)\*†                    11 774 (6.06)    1521 (5.2)       42 000 (7.19)     5609 (6)
  CCI 0, n (%)\*†                        54 116 (27.83)   5845 (19.97)     191 839 (32.85)   22 294 (23.84)
  CCI 1, n (%)\*†                        97 047 (49.91)   15 437 (52.73)   283 688 (48.59)   48 600 (51.97)
  CCI≥2, n (%)\*†                        43 278 (22.26)   7992 (27.3)      108 371 (18.56)   22 629 (24.2)
  CAT, n (%)\*†                          22 383 (11.51)   1675 (5.72)      77 695 (13.31)    6158 (6.58)
  Bronchial fibroscopy, n (%)\*†         4859 (2.5)       467 (1.6)        20 039 (3.43)     2061 (2.2)
  Non-invasive MV, n (%)\*†              3563 (1.83)      1065 (3.64)      9250 (1.58)       3301 (3.53)
  Invasive MV, n (%)\*†                  1937 (1)         1673 (5.71)      7248 (1.24)       6699 (7.16)
  Thoracocentesis, n (%)\*†              3610 (1.86)      358 (1.22)       13 535 (2.32)     1415 (1.51)
  Red cell transfusion, n (%)\*†         6866 (3.53)      1413 (4.83)      19 626 (3.36)     5313 (5.68)
  Readmission, n (%)\*†                  24 306 (12.5)    6459 (22.06)     66 353 (11.36)    18 582 (19.87)
  LOHS, median (IQR) \*†                 8 (5--12)        6 (2--12)        8 (5--12)         6 (2--13)
  *Streptococcus pneumoniae*, n (%)\*†   28 086 (14.44)   2457 (8.39)      89 171 (15.27)    8085 (8.64)
  *Legionella*, n (%)\*†                 1766 (0.91)      95 (0.32)        6134 (1.05)       349 (0.37)
  *Staphylococcus aureus*, n (%)\*†      1042 (0.54)      232 (0.79)       3017 (0.52)       795 (0.85)
  *Haemophilus influenzae*, n (%)\*†     763 (0.39)       29 (0.1)         2704 (0.46)       129 (0.14)
  *Pseudomonas aeruginosa*, n (%)\*†     1400 (0.72)      270 (0.92)       4934 (0.85)       1086 (1.16)

\*Significant differences (p\<0.05) when comparing 'alive' versus 'died' subjects without diabetes.

†Significant differences (p\<0.05) when comparing 'alive' versus 'died' subjects with diabetes.

AMI, acute myocardial infarction; CAT, computerised axial tomography of thorax; CCI, Charlson Comorbidity Index; CEVD/HP/PAPL, cerebrovascular disease/hemiplegia/paraplegia; CHF, congestive heart failure; LOHS, length of hospital stay; MV, mechanical ventilation; PVD, peripheral vascular disease.

For the entire time period, IHM was slightly but significantly higher among those without diabetes (13.81%vs 13.09%).

Overall, patients with T2DM who died during their hospitalisation were significantly older (81.48; SD=8.94 years) than those that survived (76.42; SD=10.51 years) and had more coexisting medical conditions. Including higher prevalence of acute myocardial infarction (5.41% vs 4.71%), congestive heart failure (21.81% vs 18.05%), vascular disease (6.58% vs, 6.07%), cerebrovascular disease/hemiplegia/paraplegia (16.52% vs 9.36%), dementia (21.93% vs 9.6%), renal disease (18.28% vs 15%) and any type of malignancy (12.57% vs 7.25%). On the other hand, chronic obstructive pulmonary disease, obesity and pleuritis were more prevalent in diabetic patients that did not die during their hospital stay.

Invasive and non-invasive mechanical ventilation and red cell transfusion procedures were significantly more used in diabetic patients who died than in those that survived (5.71%, 3.64% and 4.83% vs 1%, 1.83% and 3.53%, respectively). However, CAT of thorax, thoracocentesis, bronchial fibroscopy were more frequent in T2DM and non-diabetic patients that survived than in those who died.

As can been seen in [table 3](#BMJOPEN2016013097TB3){ref-type="table"}, non-diabetic patients who died were significantly older, had more coexisting conditions like acute myocardial infarction, congestive heart failure, vascular disease, cerebrovascular disease/hemiplegia/paraplegia, dementia, renal disease and any type of malignancy, and underwent invasive and non-invasive mechanical ventilation and red cell transfusion procedures more than those non-diabetic patients that survived.

We found that 22.06% of diabetic patients that died and 12.5% of diabetic patients that survived were readmission (p\<0.01). LOHS was 6 days in those diabetic and non-diabetic patients who died vs 8 days in those diabetic and non-diabetic patients that survived.

*S pneumoniae* was more frequently detected in patients who lived than in those who died in T2DM and non-diabetic patients (14.44% vs 8.39% and 15.27% vs 8.64%), as can been seen in [table 3](#BMJOPEN2016013097TB3){ref-type="table"}.

In [table 4](#BMJOPEN2016013097TB4){ref-type="table"}, we can see the results of the multivariate analysis of the factors independently associated with IHM in diabetic and non-diabetic patients during hospital admission for CAP in Spain for the period 2004--2013.

###### 

Multivariate analysis of the factors potentially associated with in-hospital mortality for patients with and without type 2 diabetes in Spain, 2001--2013, with pneumonia as primary diagnosis

                                 Diabetes OR (95% CI)     No diabetes OR (95% CI)   Total OR (95% CI)
  ------------------------------ ------------------------ ------------------------- ------------------------
  Age, years                                                                        
   40--64                        1                        1                         1
   65--74                        1.47 (1.38 to 1.57)      1.47 (1.42 to 1.51)       1.46 (1.42 to 1.50)
   75--84                        2.70 (2.55 to 2.87)      2.49 (2.42 to 2.55)       2.53 (2.47 to 2.59)
   ≥85                           4.75 (4.47 to 5.05)      4.52 (4.40 to 4.64)       4.55 (4.44 to 4.66)
  CCI                                                                               
   0                             1                        1                         1
   1                             1.35 (1.30 to 1.39)      1.28 (1.26 to 1.31)       1.30 (1.28 to 1.32)
   ≥2                            1.50 (1.44 to 1.56)      1.44 (1.41 to 1.47)       1.46 (1.43 to 1.48)
  Obesity                        0.51 (0.48 to 0.54)      0.50 (0.47 to 0.52)       0.50 (0.48 to 0.52)
  Non-invasive MV                2.04 (1.89 to 2.21)      2.01 (1.92 to 2.11)       2.02 (1.94 to 2.10)
  Invasive MV                    11.53 (10.68 to 12.45)   12.55 (12.06 to 13.06)    12.34 (11.91 to 12.78)
  Red cell transfusion           1.14 (1.07 to 1.21)      1.35 (1.31 to 1.40)       1.30 (1.26 to 1.34)
  Readmission                    1.91 (1.85 to 1.97)      1.85 (1.82 to 1.89)       1.87 (1.84 to 1.90)
  CAT                            0.54 (0.51 to 0.57)      0.53 (0.51 to 0.55)       0.53 (0.52 to 0.55)
  Thoracocentesis                0.82 (0.73 to 0.93)      0.86 (0.80 to 0.91)       0.85(0.80 to 0.90)
  Bronchial fibroscopy           0.75 (0.67 to 0.83)      0.71 (0.67 to 0.75)       0.72 (0.68 to 0.75)
  *Streptococcus pneumoniae*\*   0.54 (0.52 to 0.57)      0.52 (0.51 to 0.53)       0.52 (0.51 to 0.54)
  *Legionella*\*                 0.43 (0.34 to 0.53)      0.38 (0.34 to 0.42)       0.39 (0.35 to 0.43)
  *Staphylococcus aureus*\*      1.22 (1.04 to 1.42)      1.26 (1.16 to 1.37)       1.25 (1.16 to 1.35)
  *Haemophilus influenzae*\*     0.22 (0.15 to 0.32)      0.26 (0.21 to 0.31)       0.25 (0.21 to 0.29)
  Year                           0.97 (0.96 to 0.99)      0.97 (0.96 to 0.98)       0.97 (0.96 to 0.98)
  Diabetes                                                −                         0.92 (0.91 to 0.94)

\*The pathogen ORs are all relative to the baseline of 'no pathogen identified'.

CAT, computerised axial tomography of thorax; CCI, Charlson Comorbidity Index; MV, mechanical ventilation.

Among diabetic patients, IHM was significantly higher in older subjects (vs \<40--64-year old, OR 4.75, 95% CI 4.47 to 5.05 for ≥85-year old) and in those with more comorbidities according to the CCI (vs no comorbidities, OR 1.35, 95% CI 1.30 to 1.39, for one comorbidity; OR 1.50, 95% CI 1.44 to 1.56, for two or more comorbidities).

For diabetic patients, IHM was significantly lower in obese persons (OR 0.51, 95% CI 0.48 to 0.54) than in those with normal body mass index.

Over the entire study period, a diabetic patient with readmission was 1.14 (95% CI 1.07 to 1.21) times more likely to die than a diabetic patient without readmission.

Patients with T2DM having an in-hospital infection during admission for CAP (*S pneumoniae or Legionella or H influenzae* were identified) had lower probability of dying than patients without these pathogens. However, diabetic patients with *S aureus* had 1.22-fold higher probability of dying during their stay than those without that pathogen. IHM was significantly higher in patients who underwent invasive and non-invasive mechanical ventilation (OR 11.53, 95% CI 10.68 to 12.45 and OR 2.04, 95% CI 1.89 to 2.21) and red cell transfusion (OR 1.14, 95% CI 1.07 to 1.21).

Diabetic patients who underwent CAT of thorax, bronchial fibroscopy and thoracocentesis procedures had a 0.54-fold, 0.75-fold and 0.82-fold, respectively, lower probability of dying during their stay than those who did not undergo these procedures.

Time trend analysis showed a minor but significant decrease in IHM from 2004 to 2013 in patients with T2DM (OR 0.97, 95% CI 0.96 to 0.99).

As can been seen in [table 4](#BMJOPEN2016013097TB4){ref-type="table"}, for non-diabetic patients, IHM was significantly higher in older persons, in those with more comorbidities, in those with readmissions, in those with infections of *S aureus* and in those who underwent invasive and non-invasive mechanical ventilation and red cell transfusion procedures. As for diabetic patients, we found a significant decrease in mortality over time.

In our study, suffering diabetes was associated with a lower IHM (OR 0.92, 95% CI 0.91 to 0.94).

Finally, for the entire population, time trend analyses showed a significant decrease in mortality from 2004 to 2013 in patients admitted for CAP in Spain (OR 0.97, 95% CI 0.96 to 0.98).

Discussion {#s4}
==========

Using data from the CMBD, we found that rates of hospitalisation for CAP in patients with and without T2DM increased significantly from 2004 to 2013. These results are consistent with a report from Denmark, which pointed that total pneumonia hospitalisation increased by 63%, from 4.96 per 1000 population in 1997 to 8.09 in 2011.[@R12] Recently, Quan *et al* in Oxfordshire, UK, concluded that hospital admissions for CAP increased by ∼9% per year between 2009 and 2014.[@R9] The authors concluded that there was no evidence that the increase was caused by more low-severity cases presenting to hospital,[@R9] and that the ageing population only explains part of the increase.[@R3] [@R9] [@R17]

We found that readmissions for CAP increased over time in patients with and without T2DM and LOHS decreased in both groups of patients. These data are consistent with other published study, suggesting that the fact that readmissions for pneumonia increased over time supports another plausible explanation for the shortening of LOHS, namely, an increased pressure for early discharge.[@R9] [@R18]

After adjusting for age and sex, we found that the incidence of CAP among patients with T2DM was 1.66-times higher than among non-diabetic patients. Our results agree with the Fremantle Diabetes Study data, in this study Hamilton *et al* compared patients with T2DM in Australia to matched non-diabetic subjects and indicated that IRR for pneumonia was 1.86 (95% CI 1.55 to 2.21).[@R6] In the USA, Jackson *et al*[@R19] also reported that the adjusted RR for hospitalisations for CAP was 1.52 (95% CI 1.29 to 1.78) among patients with diabetes compared with patients without diabetes, based on 46 237 subjects aged \>65 years. In a Canadian study, the authors indicated that patients with diabetes had an increased risk of pneumonia-related hospitalisation than those without diabetes (RR 1.46, 95% CI 1.42 to 1.49).[@R8] In a case--control study in Denmark, Kornum *et al*[@R4] found that T2DM was associated with a 1.2-fold increased risk of a pneumonia-related hospitalisation. They concluded that longer duration of diabetes and poor glycaemic control increase the risk of CAP-related hospitalisation.

Like other authors, we found that patients admitted for CAP were increasingly older over time.[@R9] [@R17] In the UK, using linked electronic health records of patients with diabetes, McDonald *et al*[@R20] observed that pneumonia incidence was 6--8 times higher among patients aged ≥85 years than patients aged 65--69 years. Possible explanations include a general improvement in clinical management, especially changes in immunosuppressive regimens and handling of comorbidities.[@R12]

In our study, patients with T2DM had a higher number of simultaneous comorbidities and were more frequently obese, but obesity was not associated with a higher mortality risk during admission for CAP. Obesity is known to have adverse effects on immune function and to increase susceptibility to infections such as pneumonia;[@R21] however, Hamilton *et al*[@R6] concluded that a high body mass index was independently associated with any infection in their cohort of diabetic patients. A recent meta-analysis concluded that overweight and obesity were significantly associated with reduced risk of pneumonia mortality (RR 0.83, 95% CI 0.77 to 0.91, p\<0.01) and suggests that an 'obesity survival paradox' exists for pneumonia.[@R22]

The use of non-invasive mechanical ventilation has shown an over threefold increase in patients with and without T2DM over the study period. In a study about CAP in elderly, the authors found that mechanical ventilation was provided to 31.8% of patients and that almost half of the patients older than 90 years who received such care were discharged alive, supporting the belief that such care for the critically ill elderly patient is often justified.[@R11] Our investigation showed that mechanical ventilation was a strong risk factor for IHM in both groups studied. However, given our study design it is not possible, with our data, to determine if mechanical ventilation is effective for critically ill elderly patient with CAP.

As expected, *S pneumoniae* was the most frequent aetiological agent among patients with and without diabetes; however, its dominance is decreasing. Smith *et al* concluded that declines in cases of pneumonia due to *S pneumoniae* (from 7.1% in 1993 to 2.3% 2011) may be related to more frequent and effective vaccination, which reduces the risk of invasive pneumococcal disease and bacteraemia.[@R23] Also, this reduced risk may have resulted in less frequent coding because more thorough diagnostic evaluations accompany a higher severity of disease. In Spain *S pneumoniae* vaccine is recommended for high-risk groups, including people with diabetes, and for all persons aged 65 years or over.[@R24]

We found that other organism\'s particularly *S aureus* was more prevalent in dead patients than in survivors in patients with T2DM and non-diabetic patients. Like other authors, despite the trends observed,[@R23] [@R25] the low incidence of *S aureus* (0.57% in patients with T2DM and 0.56% in those without T2DM), perhaps suggests that *S aureus* is not routinely searched for and detected for patients with CAP.[@R23] [@R26] It has been reported that pneumonia is the leading infectious cause of death in Spain; however, the mortality rate for pneumonia has decreased between 1980 and 2011.[@R27] In our study, we found that crude IHM decreased over time among diabetic and non-diabetic patients with a diagnosis of CAP. Simonetti *et al*[@R28] found a progressive downward trend of 30-day mortality in hospitalised patients with CAP (−0.2% death/year; p for trend =0.003) and concluded that the decrease~~s~~ in mortality rates suggest general improvement in the management of CAP.

We detected that patients with T2DM who died during their stay were older, had more coexisting comorbid conditions and had significantly more readmissions than those patients with T2DM that survived. In diabetic patients who died, mechanical ventilation and red cell transfusion were significantly more used than in those that survived. One possible explanation is that there is a trend to hospitalise a higher proportion of fragile or terminal patients who previously may have been treated at home.[@R12]

In our population, the presence of T2DM was not a risk factor of death during admission for CAP. The results add important evidence to previous information. In an observational cohort study of all Medicare recipients, aged 65 years or older, hospitalised in non-federal US hospitals, Kaplan *et al*[@R11] reported no association between IHM and diabetes. In a Canadian study of 2471 patients with CAP, the authors concluded that hyperglycaemia, not the presence of diabetes, was the only factor having a significant negative effect on patient survival.[@R29] However, Kornum *et al*[@R5] indicated that high glucose levels were associated with increased mortality in patients with and without T2DM. Perhaps, the fact is that patients with diabetes are more likely to be hospitalised with less severity. In fact, in our study, we observed a lower frequency of pleuritis and any type of malignancy in diabetics than in non-diabetics, which could justify the lower mortality in the first group. Finally, we think that this T2DM result is part of the obesity paradox.[@R22]

In our study, mechanical ventilation (invasive and non-invasive) and red cell transfusion were significantly associated with mortality during admission for CAP in groups of patients with and without diabetes.

A recent study reported that non-invasive pressure ventilation is frequently used in CAP but is associated with high failure rates, and indicated that patients who failed non-invasive mechanical ventilation had an increased odds of death when compared with patients who were treated with invasive ventilation (OR 2.2, 95% CI 1.0 to 4.8, p=0.03).[@R30]

The strengths of our findings lie in the large sample size, the 10-year follow-up period and the standardised methodology, which has been used to investigate diabetes and its complications in Spain and elsewhere.[@R31]

Limitations of the study {#s4a}
------------------------

Nevertheless, our study is subject to several limitations. Our data source was the CMBD, an administrative database that contains discharge data for hospitalisations in Spain and uses information the physician has included in the discharge report. Therefore, our findings are limited by the lack of data, precluding adjustment for pneumococcal and influenza vaccinations, which have been associated with reduced mortality among patients hospitalised with pneumonia.[@R5] A further limitation is the use of IHM which misses patients who may have died soon after discharge.

Other studies have identified factors that may influence in CAP outcomes and that were not included in our investigation because these variables were not collected in the CMBD. These factors include, among others, illness severity or antimicrobial treatments.[@R32] Additionally, we also cannot identify whether gradual changes were made in referral practice during the study period.

Another significant limitation is the fact that we did not classify diabetic patients into groups based on the therapy used to control blood glucose, with the result that we were unable to provide data on the control of blood glucose during the hospitalisation.

The ICD-9-CM used in the CMBD does not contain any codes specifically for CAP but only has more general codes for pneumonia. Therefore, the ICD-9-CM cannot differentiate a CAP from a hospital-acquired pneumonia (HAP). In the CMBD database, the first diagnosis is the main reason why a patient is admitted to the hospital. By definition a patient with HAP has to acquire this infection after admission to the hospital. Therefore, according to this methodology, it is very improbable that an HAP could appear as a first diagnosis. The only possible situation for this would be that a patient previously hospitalised, and discharged from the hospital, would return in the first days with a pneumonia acquired in the previous hospitalisation. As commented before, we belief this is an extremely improbable situation that would only have a very small impact on the results. Furthermore, cases with a primary diagnosis of pneumonia (ICD-9-CM codes: 480--488, 507.0--507.8) in the hospital discharge report has been used by other authors, such as Kaplan *et al* and Hamilton *et al*, considering those as CAP admissions.[@R6] [@R11]

Besides the limitations of administrative databases for clinical investigation on CAP, many studies have used these data sources for relevant epidemiological studies on respiratory diseases.[@R6] [@R11] [@R33] [@R34] The CMBD is periodically audited and the validity of the 'diabetes diagnosis' in hospital discharge reports has been demonstrated in the past.[@R35] However, as a result of these audits, it is possible and desirable that accuracy of coding may have improved over time so this would affect the results of our investigation and must be taken into consideration.

Conclusions {#s5}
===========

In conclusion, Spanish national data show that rates of hospitalisation for CAP in patients with and without T2DM increased significantly from 2004 to 2013 and incidence rates were higher in patients with T2DM than in those without diabetes in all time periods studied. CAP incidence seems to be increasing at a higher rate among patients with T2DM than among non-diabetic patients. IHM after CAP shows downward trend over time in all groups analysed. Remarkably, the presence of T2DM is not a risk factor of death after CAP in our cohort.
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